<DOC>
	<DOCNO>NCT03102723</DOCNO>
	<brief_summary>There remain clinical need improve health outcome patient ischemic heart disease ( IHD ) lead cause death disability Singapore worldwide . One neglect therapeutic target 'myocardial reperfusion injury ' ST-segment elevation myocardial infarction ( STEMI ) patient treat primary percutaneous coronary intervention ( PPCI ) . This result microvascular obstruction ( MVO ) cardiomyocyte death contributes upto 50 % final myocardial infarct ( MI ) size . Cangrelor , potent intravenous platelet P2Y12 inhibitor rapid onset offset action , demonstrate experimental animal study reduce MI size administer prior reperfusion . Whether Cangrelor give together Ticagrelor would effective reduce MI size STEMI patient treat PPCI know investigated Platelet Inhibition Target Reperfusion Injury ( PITRI ) trial .</brief_summary>
	<brief_title>Platelet Inhibition Target Reperfusion Injury</brief_title>
	<detailed_description>The PITRI proof-of-concept clinical trial randomise 210 STEMI patient receive either Cangrelor ( single intravenous bolus follow 120-minute infusion ) match normal/saline placebo , initiate prior PPCI top conventional oral dual antiplatelet therapy ( Aspirin + Ticagrelor ) . The primary endpoint acute MI size cardiac MRI day 3 . Secondary endpoint include incidence extent MVO cardiac MRI ; chronic MI size , leave ventricular size ejection fraction cardiac MRI 6 month .</detailed_description>
	<mesh_term>Reperfusion Injury</mesh_term>
	<mesh_term>Cangrelor</mesh_term>
	<criteria>1 . Age ≥21 &lt; 80 year age 2 . STEMI define : ≥2 mm STsegment elevation 2 anterior lead ( V1V4 ) ≥1 mV STsegment elevation 2 limb lead ( II , III aVF , I , aVL ) . ST elevation II , II , aVF less 1 mm ST depression aVL Posterior infarction ST depression ≥ 1 mm either V1 , V2 , V3 ST elevation ≥ 1 mm either V7 , V8 V9 3 . ≤12 hour onset chest pain . 1 . History previous MI , stroke , transient ischemic attack prior cardiac bypass surgery 2 . Known contraindication cardiac MRI ( CMR ) MRI contraindicate implanted device , significant claustrophobia , severe allergy gadolinium chelate contrast , severe renal insufficiency ( estimate glomerular filtration rate [ eGFR ] &lt; 30 mL/min/1.73 m2 ) 3 . Patients prior therapy within 7 day anticoagulant ( warfarin , phenindione , dabigatran , apixaban rivaroxaban ) , glycoprotein IIbIIIa inhibitor , thrombolytic therapy 4 . Significant comorbidities : Patients severe hepatic failure ( INR &gt; 2 ) Cardiac arrest reduce Glasgow Coma Scale Cardiogenic shock Poor premorbid status ( bed bound / wheelchair bound ) Collapse / comatose / semiconscious state 5 . Contraindications heparinisation AntiPlatelet Therapy : HeparinInduced Thrombocytopenia ( HIT ) Risk active bleeding ( GI bleeding , traumatic head injury ) 6 . Pregnancy 7 . Contrast allergy 8 . Patients strong CYP3A inhibitor inducer ( atazanavir , clarithromycin , indinavir , itraconazole , ketoconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin voriconazole , rifampin , dexamethasone , phenytoin , carbamazepine , phenobarbital )</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>STEMI</keyword>
	<keyword>primary percutaneous coronary intervention ( PPCI )</keyword>
	<keyword>cangrelor</keyword>
	<keyword>reperfusion</keyword>
</DOC>